You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody [61] (ab24631)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody [61]
See all Nicotinic Acetylcholine Receptor alpha 1 products (3) ...

Description

Rat monoclonal [61] to Nicotinic Acetylcholine Receptor alpha 1

Specificity

ab24631 reacts with Neuronal Nicotinic Acetylcholine Receptor a1-Subunits.

Tested applications

IF, IPmore details

Cross reactivity

Reacts with

Mouse, Human, Torpedo

Immunogen

Denatured Electophorus electricus acetylcholine receptors (AChRs).

Epitope

This antibody binds to the cytoplasmic surface of native and denatured muscle AChR a1 subunits, within amino acids 371-386.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: None
Constituents: Ascites

Concentration

Concentration information loading...

Purity

Ascites

Primary antibody notes

ab24631 is useful in studying AChR synthesis and assembly.

Clonality

Monoclonal

Clone number

61

Isotype

IgG2a

Applications

Show applications key

Our Abpromise guarantee covers the use of ab24631 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • IF

     IF: 1/250 - 1/500.

    IF: 1/250 - 1/500.

  • IP

     IP: 1/100

    IP: 1/100

Target

Function

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

Tissue specificity

Isoform 1 is only expressed in skeletal muscle. Isoform 2 is constitutively expressed in skeletal muscle, brain, heart, kidney, liver, lung and thymus.

Involvement in disease

Defects in CHRNA1 are a cause of multiple pterygium syndrome lethal type (MUPSL) [MIM:253290]. Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.
Note=The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs.
Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS) [MIM:608930]. FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.

Sequence similarities

Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-1/CHRNA1 sub-subfamily.

Cellular localization

Cell junction > synapse > postsynaptic cell membrane. Cell membrane.

Target information above from: UniProt accessionP02708 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • Acetylcholine receptor subunit alpha antibody
  • ACHA_HUMAN antibody
  • ACHRA antibody
  • ACHRD antibody
  • CHNRA antibody
  • Cholinergic receptor nicotinic alpha polypeptide 1 antibody
  • Cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) antibody
  • CHRNA antibody
  • Chrna1 antibody
  • CMS2A antibody
  • FCCMS antibody
  • Nicotinic cholinergic receptor alpha 1 antibody
  • SCCMS antibody
  • Schizophrenia neurophysiologic defect candidate antibody
see all

References for Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody [61] (ab24631)

This product has been referenced in:

  • Tzartos SJet al. Mapping of surface structures of electrophorus acetylcholine receptor using monoclonal antibodies. J Biol Chem 256:8635-45 (1981).Read more (PubMed: 6167581) »

See 1 publication for this product

Publishing research using ab24631? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"